AdoRx Therapeutics has entered into a strategic collaboration with Johnson & Johnson Innovation and the Lung Cancer Initiative at Johnson & Johnson to develop novel therapeutics for the treatment of lung cancer. Under terms of the agreement, AdoRx has granted an exclusive option to research, develop and commercialize novel antagonists within the AdoRx portfolio, and the groups will collaborate on drug discovery and preclinical development activities. Financial terms of the collaboration were not disclosed.
"We are delighted to be teaming up with Johnson & Johnson and their Lung Cancer Initiative less than two years after the creation of AdoRx,” Pete Finan, CEO of AdoRx, said. “The collaboration will facilitate the progression of AdoRx's fit-for-purpose receptor antagonists into clinical development."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!